GlycoNex (4168) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GlycoNex (4168) has a cash flow conversion efficiency ratio of -0.017x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-17.29 Million ≈ $-544.86K USD) by net assets (NT$1.01 Billion ≈ $31.84 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
GlycoNex - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how GlycoNex's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of GlycoNex for a breakdown of total debt and financial obligations.
GlycoNex Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GlycoNex ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pinar Entegre Et ve Un Sanayi AS
IS:PETUN
|
-0.017x |
|
UOB Kay Hian Securities (Thailand) Public Company Limited
BK:UOBKH
|
0.148x |
|
Empress Royalty Corp
V:EMPR
|
0.029x |
|
Tuniu Corp
NASDAQ:TOUR
|
0.002x |
|
Cell Biotech Co. Ltd
KQ:049960
|
0.033x |
|
Compass Digital Acquisition Corp
NASDAQ:CDAQ
|
0.037x |
|
AAC Clyde Space AB (publ)
ST:AAC
|
-0.034x |
|
GrandTech C.G. Systems
TWO:6123
|
-0.014x |
Annual Cash Flow Conversion Efficiency for GlycoNex (2017–2024)
The table below shows the annual cash flow conversion efficiency of GlycoNex from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see GlycoNex market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.05 Billion ≈ $32.97 Million |
NT$-221.97 Million ≈ $-6.99 Million |
-0.212x | -47.20% |
| 2023-12-31 | NT$1.28 Billion ≈ $40.21 Million |
NT$-183.92 Million ≈ $-5.79 Million |
-0.144x | -24.32% |
| 2022-12-31 | NT$1.45 Billion ≈ $45.54 Million |
NT$-167.55 Million ≈ $-5.28 Million |
-0.116x | -11.81% |
| 2021-12-31 | NT$1.36 Billion ≈ $42.81 Million |
NT$-140.86 Million ≈ $-4.44 Million |
-0.104x | -9.61% |
| 2020-12-31 | NT$1.54 Billion ≈ $48.51 Million |
NT$-145.59 Million ≈ $-4.59 Million |
-0.095x | +31.50% |
| 2019-12-31 | NT$1.30 Billion ≈ $40.98 Million |
NT$-179.58 Million ≈ $-5.66 Million |
-0.138x | -17.31% |
| 2018-12-31 | NT$1.53 Billion ≈ $48.28 Million |
NT$-180.34 Million ≈ $-5.68 Million |
-0.118x | -452.73% |
| 2017-12-31 | NT$1.84 Billion ≈ $58.01 Million |
NT$61.43 Million ≈ $1.94 Million |
0.033x | -- |
About GlycoNex
GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company's development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under preclinical stage; GNX203, glycan-directed anti… Read more